Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-046006
Filing Date
2021-07-08
Accepted
2021-07-08 17:10:04
Documents
2
Period of Report
2021-07-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1635
2 POA DOCUMENT poa.txt EX-24.3_998368 3014
  Complete submission text file 0001209191-21-046006.txt   6062
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AEGLEA BIOTHERAPEUTICS, INC. 805 LAS CIMAS PARKWAY, SUITE 100 AUSTIN TX 78746
Business Address
Alspaugh Jonathan (Reporting) CIK: 0001868112 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 211080915